DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS Spectrum Pharmaceuticals would need to study the drug further, including generating data from a randomized controlled trial, according to the release. Spectrum responded by stating that it would “de-prioritize poziotinib program activities, effective immediately.” The decision comes after the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously that the drug’s demonstrated clinical benefit did not outweigh its risks.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
